Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 318 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Lexapro Clear all
Completed Not applicable Interventional

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

NCT02297126
View directory record Official record
Conditions
Adverse Drug Reaction
Interventions
Pharmacogenetic Intervention Arm (pharmacogenetic testing)
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4,465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 23, 2026, 9:34 AM EDT
Completed Phase 2 Interventional Results available

Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant

NCT00905424
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + SPD489 (lisdexamfetamine dimesylate), Antidepressant + placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
Newport Beach, California • San Diego, California • Bradenton, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 23, 2026, 9:34 AM EDT
Not listed No phase listed Observational

Tracking Response to Antidepressants in Advance of Investigational Trials

NCT04748276
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)
Drug
Lead sponsor
Adams Clinical
Network
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 23, 2026, 9:34 AM EDT
Completed Early Phase 1 Interventional

Pilot Study to Evaluate Individualized Choice of Antidepressants in Patients With Cancer

NCT01725048
View directory record Official record
Conditions
Major Depressive Disorder, Neoplasms
Interventions
Mirtazapine, Citalopram
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 23, 2026, 9:34 AM EDT
Completed Not applicable Interventional Results available

Methylphenidate for Depressed Cancer Patients Receiving Palliative Care

NCT00129467
View directory record Official record
Conditions
Depression, Palliative Care, Cancer, Mental Disorder
Interventions
Methylphenidate, Placebo, Selective Serotonin Uptake Inhibitor (SSRI)
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 23, 2026, 9:34 AM EDT
Terminated Phase 1 Interventional

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy

NCT04951609
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Phoenix, Arizona • Anaheim, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 23, 2026, 9:34 AM EDT
Recruiting Phase 4 Interventional

Aβ Dynamics in LLMD

NCT05004987
View directory record Official record
Conditions
Alzheimer Disease, Major Depressive Disorder
Interventions
Escitalopram Oxalate, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 23, 2026, 9:34 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02418585
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • San Rafael, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 23, 2026, 9:34 AM EDT
Not listed Phase 4 Interventional

Brain Mechanisms and Targeting Insomnia in Major Depression

NCT00628914
View directory record Official record
Conditions
Major Depressive Disorder, Insomnia
Interventions
escitalopram and eszopiclone, Escitalopram, eszopiclone, and placebo, Escitalopram
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2010 · Synced Oct 23, 2026, 9:34 AM EDT
Terminated Phase 4 Interventional

Galantamine Augmentation of Escitalopram for Treatment of Depression

NCT00423969
View directory record Official record
Conditions
Depression
Interventions
Galantamine, Escitalopram
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 18, 2007 · Synced Oct 23, 2026, 9:34 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of ABT-436 in Major Depressive Disorder

NCT01741142
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ABT-436, Escitalopram, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
18
States / cities
Little Rock, Arkansas • Garden Grove, California • National City, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2013 · Synced Oct 23, 2026, 9:34 AM EDT
Terminated Phase 4 Interventional Results available

Lexapro for Major Depression in Patients With Epilepsy

NCT01244724
View directory record Official record
Conditions
Major Depression, Epilepsy
Interventions
Lexapro
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 23, 2026, 9:34 AM EDT
Completed Phase 4 Interventional

Escitalopram Treatment of Patients With Agitated Dementia

NCT00260624
View directory record Official record
Conditions
Alzheimer's Disease, Psychomotor Agitation
Interventions
Escitalopram (Lexapro)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
61 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Fairport, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2012 · Synced Oct 23, 2026, 9:34 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women

NCT00406640
View directory record Official record
Conditions
Depression, Depressive Disorder, Depressive Disorder, Major
Interventions
Desvenlafaxine succinate sustained-release (DVS SR), Escitalopram
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
52
States / cities
Peoria, Arizona • Pasadena, California • San Diego, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Oct 23, 2026, 9:34 AM EDT
Completed Phase 3 Interventional Results available

The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression

NCT00556140
View directory record Official record
Conditions
Psychotic Depression
Interventions
Aripiprazole
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Oct 23, 2026, 9:34 AM EDT
Completed Phase 2 Interventional Results available

eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients

NCT02458690
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Cardiovascular Diseases, Heart Diseases, Coronary Artery Disease, Stroke
Interventions
Beating the Blues (BtB), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Usual Care
Behavioral · Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
50 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 23, 2026, 9:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Aripiprazole and Lexapro Drug Interaction Study

NCT00361790
View directory record Official record
Conditions
Healthy
Interventions
Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7 days at 20 mg
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 23, 2026, 9:34 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

NCT03538691
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Brexpiprazole, Antidepressant therapy
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 23, 2026, 9:34 AM EDT
Completed Phase 2 Interventional Results available

Brain Function and Structure in Cocaine Dependence

NCT02080832
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Citalopram, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 23, 2026, 9:34 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder

NCT00215137
View directory record Official record
Conditions
OCD
Interventions
escitalopram, Placebo ( sugar pill)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Oct 23, 2026, 9:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Creatine Treatment for Female Adolescents With Depression Who Are Non-Responders to Fluoxetine or Escitalopram

NCT00851006
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Creatine Monohydrate
Drug
Lead sponsor
University of Utah
Other
Eligibility
13 Years to 18 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Oct 23, 2026, 9:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Treatment of Mood and Marriage Study (TOMMS)

NCT00612807
View directory record Official record
Conditions
Major Depressive Disorder, Partner Relational Disorder (V61.10)
Interventions
Weekly marital therapy, As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.
Behavioral · Drug
Lead sponsor
Duke University
Other
Eligibility
60 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 23, 2026, 9:34 AM EDT
Completed Phase 2 Interventional

TC-5214 as add-on the Treatment of Major Depressive Disorder

NCT00692445
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
TC-5214 + citalopram, Placebo + citalopram
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Miami, Florida • Cincinnati, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 23, 2026, 9:34 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Antidepressant Medication Plus Donepezil for Treating Late-life Depression

NCT00177671
View directory record Official record
Conditions
Depression, Dementia
Interventions
Escitalopram, Donepezil, Venlafaxine, Placebo, Duloxetine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 23, 2026, 9:34 AM EDT